Abiraterone acetate: A review of its use in patients with metastatic castration-resistant prostate cancer

Drugs

Volumn 73, Issue 18, 2013, Pages 2077-2091

  Hoy, Sheridan M ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ABIRATERONE ACETATE; CYTOCHROME P450 17; DOCETAXEL; PLACEBO; PREDNISONE;

ANEMIA; ANGINA PECTORIS; ARTHRALGIA; BACKACHE; BONE PAIN; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CASTRATION RESISTANT PROSTATE CANCER; DIARRHEA; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EDEMA; FATIGUE; HEART ATRIUM FIBRILLATION; HEART FAILURE; HUMAN; HYPERTENSION; HYPOKALEMIA; LIVER TOXICITY; MAXIMUM PLASMA CONCENTRATION; MULTICENTER STUDY (TOPIC); OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; TACHYCARDIA; URINARY TRACT INFECTION;

ANDROSTADIENES; CLINICAL TRIALS, PHASE III AS TOPIC; DISEASE-FREE SURVIVAL; HUMANS; MALE; MULTICENTER STUDIES AS TOPIC; PREDNISONE; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; TAXOIDS;

EID: 84892606784     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.1007/s40265-013-0150-z     Document Type: Review

References (60)

1. Bluemn EG, Nelson PS. The androgen/androgen receptor axis in prostate cancer. Curr Opin Oncol. 2012;24(3):251-7.
2. Massard C, Fizazi K. Targeting continued androgen receptor signaling in prostate cancer. Clin Cancer Res. 2011;17(12): 3876-83.
3. Horwich A, Parker C, Bangma C, et al. Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and followup. Ann Oncol. 2010;21(Suppl 5):v129-33.
4. Hotte SJ, Saad F. Current management of castrate-resistant prostate cancer. Curr Oncol. 2010;17(Suppl 2):S72-9.
5. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: prostate cancer (Version 4.2013). 2013. http://www.nccn.org/ professionals/physician-gls/pdf/prostate.pdf (Accessed 11 Nov 2013).
6. Mohler JL, Titus MA, Wilson EM. Potential prostate cancer drug target: bioactivation of androstanediol by conversion to dihydrotestosterone. Clin Cancer Res. 2011;17(18):5844-9.
7. Schweizer MT, Antonarakis ES. Abiraterone and other novel androgen-directed strategies for the treatment of prostate cancer: a new era of hormonal therapies is born. Ther Adv Urol. 2012;4(4):167-78.
8. Small EJ, Halabi S, Dawson NA, et al. Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: a phase III trial (CALGB 9583). J Clin Oncol. 2004;22(6):1025-33.
9. Attard G, Reid AH, A'Hern R, et al. Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer. J Clin Oncol. 2009;27(23):3742-8.
10. Tsao CK, Galsky MD, Small AC, et al. Targeting the androgen receptor signalling axis in castration-resistant prostate cancer (CRPC). BJU Int. 2012;110(11):1580-8.
11. Yang LP. Abiraterone acetate: in metastatic castration-resistant prostate cancer [Erratum appears in Drugs. 2012;72(2):192]. Drugs. 2011;71(15):2067-77.
12. European Medicines Agency. ZYTIGA 250 mg tablets: summary of product characteristics; 2013. http://www.ema.europa.eu/docs/en-GB/document-library/ EPAR-Product-Information/human/002321/WC500112858.pdf (Accessed 11 Nov 2013).
13. Janssen Biotech Inc. ZYTIGA (abiraterone acetate) tablets: prescribing information; 2013. http://www.accessdata.fda.gov/drugsatfda-docs/label/2013/ 202379s007lbl.pdf (Accessed 11 Nov 2013).
14. Montgomery RB, Mostaghel EA, Vessella R, et al. Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth. Cancer Res. 2008;68(11):4447-54.
15. Li R, Evaul K, Sharma KK, et al. Abiraterone inhibits 3-hydroxysteroid dehydrogenase: a rationale for increasing drug exposure in castration-resistant prostate cancer. Clin Cancer Res. 2012;18(13):3571-9.
16. Potter GA, Barrie SE, Jarman M, et al. Novel steroidal inhibitors of human cytochrome P45017a (17a-hydroxylase-C17,20-lyase): potential agents for the treatment of prostatic cancer. J Med Chem. 1995;38(13):2463-71.
17. Yamaoka M, Hara T, Kusaka M. Overcoming persistent dependency on androgen signaling after progression to castrationresistant prostate cancer. Clin Cancer Res. 2010;16(17):4319-24.
18. Ang JE, Olmos D, de Bono JS. CYP17 blockade by abiraterone: further evidence for frequent continued hormone-dependence in castration-resistant prostate cancer. Br J Cancer. 2009;100(5): 671-5.
19. Attard G, Reid AH, Yap TA, et al. Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven J Clin Oncol. 2008;26(28):4563-71.
20. [Erratum appears in J Clin Oncol. 2012;30(15):1896].
21. Ryan CJ, Smith MR, Fong L, et al. Phase I clinical trial of the CYP17 inhibitor abiraterone acetate demonstrating clinical activity in patients with castration-resistant prostate cancer who received prior ketoconazole therapy. J Clin Oncol. 2010;28(9):1481-8.
22. Efstathiou E, Titus M, Tsavachidou D, et al. Effects of abiraterone acetate on androgen signaling in castrate-resistant prostate cancer in bone. J Clin Oncol. 2012;30(6):637-43.
23. Reid AH, Attard G, Danila DC, et al. Significant and sustained antitumor activity in post-docetaxel, castration-resistant prostate cancer with the CYP17 inhibitor abiraterone acetate. J Clin Oncol. 2010;28(9):1489-95.
24. Danila DC, Morris MJ, de Bono JS, et al. Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated castration-resistant prostate cancer. J Clin Oncol. 2010;28(9):1496-501.
25. Ryan CJ, Smith MR, de Bono JS, et al. Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med. 2013;368(2):138-48.
26. de Bono JS, Logothetis CJ, Molina A, et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med. 2011;364(21):1995-2005.
27. Fizazi K, Scher HI, Molina A, et al. Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol. 2012;13(10):983-92.
28. Cai C, Balk SP. Intratumoral androgen biosynthesis in prostate cancer pathogenesis and response to therapy. Endocr Relat Cancer. 2011;18(5):R175-82.
29. Attard G, Reid AH, Olmos D, et al. Antitumor activity with CYP17 blockade indicates that castration-resistant prostate cancer frequently remains hormone driven. Cancer Res. 2009;69(12): 4937-40.
30. Cai C, Chen S, Ng P, et al. Intratumoral de novo steroid synthesis activates androgen receptor in castration-resistant prostate cancer and is upregulated by treatment with CYP17A1 inhibitors. Cancer Res. 2011;71(20):6503-13.
31. Mostaghel EA, Marck BT, Plymate SR, et al. Resistance to CYP17A1 inhibition with abiraterone in castration-resistant prostate cancer: induction of steroidogenesis and androgen receptor splice variants. Clin Cancer Res. 2011;17(18):5913-25.
32. van Soest RJ, van Royen ME, de Morrée ES, et al. Effects on androgen receptor nuclear import by docetaxel, cabazitaxel, abiraterone, and enzalutamide: potential mechanism for crossresistance in castration-resistant prostate cancer (CRPC) [abstract no. 5064]. J Clin Oncol. 2013;31(15 Suppl 1).
33. Ryan CJ, Shah S, Efstathiou E, et al. Phase II study of abiraterone acetate in chemotherapy-naive metastatic castration-resistant prostate cancer displaying bone flare discordant with serologic response. Clin Cancer Res. 2011;17(14):4854-61.
34. Tolcher AW, Chi KN, Shore ND, et al. Effect of abiraterone acetate plus prednisone on the QT interval in patients with metastatic castration-resistant prostate cancer. Cancer Chemother Pharmacol. 2012;70(2):305-13.
35. Marbury T, Stonerock R, Acharya M, et al. A phase 1 single-dose open-label pharmacokinetic (PK) study of abiraterone acetate (AA) in male subjects with mild or moderate hepatic impairment [abstract no. 7055]. Eur J Cancer. 2011;47:S501.
36. Marbury T, Stonerock R, Tran N, et al. A phase 1 single dose open-label reduced/staged pharmacokinetic (PK) and safety study of abiraterone acetate (AA) in men with impaired renal function [abstract no. 7057]. Eur J Cancer. 2011;47:S502.
37. Chi KN, Tolcher A, Lee P, et al. Effect of abiraterone acetate plus prednisone on the pharmacokinetics of dextromethorphan and theophylline in patients with metastatic castration-resistant prostate cancer. Cancer Chemother Pharmacol. 2013;71(1): 237-44.
38. Logothetis CJ, Basch E, Molina A, et al. Effect of abiraterone acetate and prednisone compared with placebo and prednisone on pain control and skeletal-related events in patients with metastatic castration-resistant prostate cancer: exploratory analysis of data from the COU-AA-301 randomised trial. Lancet Oncol. 2012;13(12):1210-7.
39. Sternberg CN, Molina A, North S, et al. Effect of abiraterone acetate on fatigue in patients with metastatic castration-resistant prostate cancer after docetaxel chemotherapy. Ann Oncol. 2013;24(4):1017-25.
40. Harland S, Staffurth J, Molina A, et al. Effect of abiraterone acetate treatment on the quality of life of patients with metastatic castration-resistant prostate cancer after failure of docetaxel chemotherapy. Eur J Cancer 2013;49(17):3648-57.
41. Saad F, Shore ND, Van Poppel H, et al. Abiraterone acetate in metastatic castration-resistant prostate cancer patients without prior chemotherapy: interim analysis of the COU-AA-302 phase 3 trial [abstract no. 713]. J Urol. 2013;189(4 Suppl):e293.
42. Shore N, Ryan CJ, Mulders P, et al. The impact of abiraterone acetate therapy on patient-reported pain and functional status in chemotherapy- naïve patients with progressive, metastatic castration-resistant prostate cancer: results from an updated analysis [abstract no. 784]. J Urol. 2013;189(4 Suppl):e323.
43. Scher HI, Heller G, Molina A, et al. Evaluation of circulating tumor cell (CTC) enumeration as an efficacy response biomarker of overall survival (OS) in metastatic castration-resistant prostate cancer (mCRPC): planned final analysis (FA) of COU-AA-301, a randomized, double-blind, placebo-controlled, phase III study of abiraterone acetate (AA) plus low-dose prednisone (P) post docetaxel [abstract no. LBA4517]. J Clin Oncol. 2011;29(18 Suppl 2).
44. Goodman OB, Flaig TW, Molina A, et al. Exploratory analysis of the visceral disease (VD) patient subset in COU-AA-301, a phase III study of abiraterone acetate (AA) in metastatic castrationresistant prostate cancer (mCRPC) [abstract no. 14]. J Clin Oncol. 2013;31(Suppl 6).
45. European Medicines Agency. Assessment report: Zytiga (abiraterone); 2012. http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Assessment-Report- Variation/human/002321/WC500137814.pdf (Accessed 11 Nov 2013).
46. Rathkopf DE, Smith MR, de Bono JS, et al. Long-term safety and efficacy analysis of abiraterone acetate (AA) plus prednisone (P) in metastatic castration-resistant prostate cancer (mCRPC) without prior chemotherapy (COU-AA-302) [abstract no. 5009]. J Clin Oncol. 2013;31(15 Suppl 1).
47. Heidenreich A, Bolla M, Joniau S, et al. Guidelines on prostate cancer; 2011. http://www.uroweb.org/gls/pdf/08-Prostate-Cancer.pdf (Accessed 11 Nov 2013).
48. European Medicines Agency. Xtandi 40 mg soft capsules: summary of product characteristics; 2013. http://www.ema.europa.eu/docs/en-GB/document-library/ EPAR-Product-Information/human/002639/WC500144996.pdf (Accessed 11 Nov 2013).
49. Astellas Pharma US Inc. XTANDI (enzalutamide) capsules for oral use: prescribing information; 2012. http://www.accessdata.fda.gov/drugsatfda-docs/ label/2012/203415lbl.pdf (Accessed 11 Nov 2013).
50. Scher HI, Fizazi K, Saad F, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med. 2012;367(13):1187-97.
51. Rescigno P, Buonerba C, Bellmunt J, et al. New perspectives in the therapy of castration resistant prostate cancer. Curr Drug Targets. 2012;13(13):1676-86.
52. Plosker GL. Sipuleucel-T: in metastatic castration-resistant prostate cancer. Drugs. 2011;71(1):101-8.
53. Mottet N, Bellmunt J, Bolla M, et al. EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castrationresistant prostate cancer. Eur Urol. 2011;59(4):572-83.
54. McKeage K. Docetaxel: a review of its use for the first-line treatment of advanced castration-resistant prostate cancer. Drugs. 2012;72(11):1559-77.
55. Keating GM. Cabazitaxel: a guide to its use in hormone-refractory metastatic prostate cancer. Drugs Aging. 2013;30(5):359-65.
56. National Institute for Health and Clinical Excellence. Abiraterone for castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen (NICE technology appraisal guidance 259); 2012. http://guidance.nice.org.uk/TA259/Guidance/pdf/English (Accessed 11 Nov 2013).
57. Pereira ML, Bahmdouni LS, Pepe C, et al. Cost-effectiveness analysis of abiraterone for the treatment of advanced prostate cancer under the Brazilian private health care system [abstract no. PCN86]. Value Health. 2012;15(7):A424-5.
58. Persson U, Nilsson S, Hjortsberg C, et al. Economic evaluation of abiraterone acetate as treatment for metastatic castration resistant prostate cancer after failure of docetaxel in Sweden [abstract no. PCN66]. Value Health. 2012;15(4):A219.
59. Wilson LS, Zhong L, Pon V, et al. Cost effectiveness analysis of new treatments for metastatic castration-resistant prostate cancer: does severity matter? [abstract no. PCN72]. Value Health. 2012;15(4):A220-1.
60. Scher HI, Halabi S, Tannock I, et al. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol. 2008;26(7):1148-59.